Gene · 23533
PIK3R5: phosphoinositide-3-kinase regulatory subunit 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PIK3R5: phosphoinositide-3-kinase regulatory subunit 5. Genes, record 23533. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/23533
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q8WYR1 | Phosphoinositide 3-kinase regulatory subunit 5 | 880 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 13798 | Q8WYR1 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 13798 | Q8WYR1 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 7640 | Q8WYR1 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 7641 | Q8WYR1 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 63172 | Q8WYR1 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 63174 | Q8WYR1 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 166143 | Q8WYR1 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 166145 | Q8WYR1 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 8487 | Q8WYR1 | Espacenet |
| US 10918740 B2 | 2021-02-16 | 9242 | Q8WYR1 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APITOLISIB | CHEMBL1922094 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| AZD-6482 | CHEMBL2165191 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| BGT-226 | CHEMBL3545096 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| BGT-226 FREE BASE | CHEMBL3218578 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| BUPARLISIB | CHEMBL2017974 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| DACTOLISIB | CHEMBL1879463 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| DS-7423 | CHEMBL3545248 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| GEDATOLISIB | CHEMBL592445 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| GSK-1059615 | CHEMBL3544966 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
| IZORLISIB | CHEMBL1684984 | PI3-kinase class I inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials203
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07447076 | PAXALISIB | PHASE2 | ClinicalTrials.gov | |
| NCT07391215 | PAXALISIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07287202 | PAXALISIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06757634 | GEDATOLISIB | PHASE3 | ClinicalTrials.gov | |
| NCT06208657 | PAXALISIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06190899 | GEDATOLISIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05501886 | GEDATOLISIB | PHASE3 | ClinicalTrials.gov | |
| NCT05183204 | PAXALISIB | PHASE2 | ClinicalTrials.gov | |
| NCT05009992 | PAXALISIB | PHASE2 | ClinicalTrials.gov | |
| NCT04906096 | PAXALISIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 203
See all 203 trialsNIH grants680
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PIK3R5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| I01BX002301 | Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival | 2 | 2025 |
| K12CA090625 | Vanderbilt Clinical Oncology Research Career Development Award | 2 | 2025 |
| P01CA096832 | NORMAL & NEOPLASTIC GROWTH IN THE BRAIN | 2 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 2 | 2025 |
| R01CA167426 | Role of PI3Kgamma in Tumor Progression and Metastasis | 2 | 2025 |
| R35GM136397 | GPCR anterograde trafficking | 2 | 2025 |
1 to 10 of 680Source NIH's project files
See all 680 nih grantsPapers819
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML. | BMC Cancer | 2026 | 42464230 | PubTator, text mining | PubMed |
| Systemic Drug Effects in Vortioxetine-Induced Time-Series Datasets. | Int J Mol Sci | 2026 | 42450323 | PubTator, text mining | PubMed |
| Screening of Inflammatory Biomarkers in Atherosclerosis Based on WGCNA Analysis and Machine Learning. | Curr Mol Med | 2026 | 42227555 | PubTator, text mining | PubMed |
| Mapping functional non-coding variation in individual human genomes through haplotyping, multiomics, and deep learning. | Nat Commun | 2026 | 42056104 | PubTator, text mining | PubMed |
| Leveraging Deep Learning to Construct a Programmed Cell Death-Driven Prognostic Signature in Acute Myeloid Leukemia. | Curr Issues Mol Biol | 2026 | 42042014 | PubTator, text mining | PubMed |
| ALOX5 Expression and Pathomics Features Reveal New Insights Into Lung Adenocarcinoma Prognosis: Model Construction and Functional Validation. | Hum Mutat | 2026 | 41809565 | PubTator, text mining | PubMed |
| New Dual Pan-PI3K/mTOR Inhibitor: Design, Synthesis, Cytotoxic Action, Permeation, Metabolic Stability, and In Silico Protein-Ligand Interaction. | ACS Omega | 2026 | 41726721 | PubTator, text mining | PubMed |
| NF-κB and STAT3 signaling uniquely stratify survival in female glioblastoma patients. | iScience | 2026 | 41716996 | PubTator, text mining | PubMed |
| Effects of ascorbic acid on trabecular meshwork gene expression and collagen secretion. | BMJ Open Ophthalmol | 2026 | 41692493 | PubTator, text mining | PubMed |
| The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke. | Sci Rep | 2025 | 41136446 | PubTator, text mining | PubMed |
1 to 10 of 819
See all 819 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/23533
GET https://conductscience.org/api/genes/v1/23533/patents?page=2